微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 50.03% | -9.57% | -3.6% | 11/159 | 43.62% | 恩华药业 | 71.67% | 行业排名> |
| 2026-06-30 | 51.9% | -6.7% | -5.65% | 72/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 55.01% | -3.18% | -1.36% | 68/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 55.77% | -13.39% | 0.79% | 61/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 55.33% | -12.73% | -0.54% | 64/159 | -2.12% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 55.63% | -14.54% | -2.09% | 63/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 56.82% | -12.34% | -11.76% | 57/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 64.39% | -7.13% | 1.56% | 43/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 63.4% | -8.48% | -2.61% | 42/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 65.1% | -6.97% | 0.43% | 42/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 64.82% | -8.43% | -6.51% | 37/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 69.33% | -5.67% | 0.08% | 34/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 69.27% | -5.54% | -1.01% | 36/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 69.98% | -2.3% | -1.14% | 36/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 70.78% | -3.48% | -3.7% | 36/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 73.5% | 2.84% | 0.22% | 34/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 73.34% | 3.94% | 2.39% | 36/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 71.63% | 0.04% | -2.32% | 38/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 73.33% | 1.41% | 2.61% | 35/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 71.47% | 4.96% | 1.29% | 40/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 70.56% | 1.08% | -1.46% | 35/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 71.6% | 0.17% | -0.98% | 35/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 72.31% | 1.1% | 6.2% | 27/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 68.09% | -5.12% | -2.45% | 43/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 69.8% | 0.52% | -2.35% | 33/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 71.48% | 2.33% | -0.06% | 28/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 71.52% | 9.02% | -0.34% | 25/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 71.76% | 18.04% | 3.35% | 36/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 69.44% | 15.23% | -0.59% | 27/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 69.85% | 21.33% | 6.47% | 29/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 65.61% | 14.96% | 7.91% | 29/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 60.8% | 24.47% | 0.89% | 50/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 60.26% | 35.07% | 4.67% | 40/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 57.57% | 44.11% | 0.89% | 44/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.07% | 44.97% | 16.84% | 44/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 48.84% | 16.8% | 9.48% | 65/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 44.62% | 12.71% | 11.68% | 52/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 39.95% | 5.14% | 1.49% | 61/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 39.37% | 8.81% | -5.87% | 49/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 41.82% | 12.8% | 5.65% | 64/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 39.58% | 15.44% | 4.18% | 45/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 38% | 4.7% | 5.02% | 55/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 36.18% | 6.15% | -2.41% | 48/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |